Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Karo Bio USA

Division of Karo Bio AB/Karo Bio USA

Latest From Karo Bio USA

Private Equity Firm EQT Hopes Higher Cash Offer Will Win It Karo Pharma

Private equity firm EQT hopes a higher cash offer for Swedish specialty pharma group Karo Pharma than the one it made two months ago will persuade reluctant shareholders in the biotech to now sell their holdings.

M & A Commercial

Madrigal's Early Phase IIb NASH Data Show Clinically Meaningful Fat Reduction

Analysts and investors also voice excitement about the THR-beta agonist's lipid-lowering effects to date. For Madrigal, the key will be replicating its 12-week data at 36 weeks, when the trial ends.

Clinical Trials Liver & Hepatic

Madrigal Believes It Holds The Key To NASH: Clearing The Fat

Emerging Company Profile: With its first-in-class selective THR beta agonist, Madrigal thinks it may have a candidate, now in Phase II, that will offer reversal of liver damage in NASH patients with an excellent safety profile. It hopes to begin Phase III studies with MGL-3196 before the end of 2018.

StartUps and SMEs Business Strategies

Screening the Screeners

A host of start-ups want to make high-volume screening the method of choice for finding drug leads and for discovering the uses for those new, mysterious targets pouring out of the genetic databases, But few of the new firms are basing their long-term plans on screening services; most are either using their systems to look for their own drugs or still evolving their business plans along with their technologies.
BioPharmaceutical Platform Technologies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Novalon Pharmaceutical Corp.
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Karo Bio AB
  • Senior Management
  • Dana M Fowlkes, MD, PhD, Chmn. & CEO
    D. J Smith, Pres.
    Clay B Thorp, Dir., Corp. Dev.
  • Contact Info
  • Karo Bio USA
    Phone: (919) 474-8888
    4222 Emperor Blvd.
    Suite 560
    Durham, NC 27703-8466